Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,883
Employees75,883
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,883
Employees75,883

NVS Key Statistics

Market cap
263.94B
Market cap263.94B
Price-Earnings ratio
16.49
Price-Earnings ratio16.49
Dividend yield
2.69%
Dividend yield2.69%
Average volume
1.83M
Average volume1.83M
High today
$123.23
High today$123.23
Low today
$121.98
Low today$121.98
Open price
$122.64
Open price$122.64
Volume
1.46M
Volume1.46M
52 Week high
$133.55
52 Week high$133.55
52 Week low
$96.06
52 Week low$96.06

NVS News

TipRanks 1d
Novartis reports NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective

Novartis (NVS) presented new ianalumab data in Sjogren’s disease at a late-breaker presentation during the American College of Rheumatology Convergence congress...

TipRanks 2d
Novartis AG Reports Strong Q3 2025 Earnings Growth

Novartis AG ( (NVS) ) has released its Q3 earnings. Here is a breakdown of the information Novartis AG presented to its investors. Elevate Your Investing Strat...

TipRanks 2d
Novartis AG Earnings Call: Growth Amid Challenges

Novartis AG ((NVS)) has held its Q3 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Prem...

Analyst ratings

63%

of 27 ratings
Buy
18.5%
Hold
63%
Sell
18.5%

More NVS News

TipRanks 2d
Tourmaline Bio acquisition completed by Novartis

Novartis (NVS) announced that it has successfully completed its acquisition of Tourmaline Bio (TRML). With the completion of the acquisition, shares of the comm...

Investor's Business Daily 2d
Novartis Slips As Generics Champ At Heart-Failure Drug In Mixed Third Quarter

Novartis (NVS) stock slipped early Tuesday after the pharma company reported core earnings of $2.25 per share on $13.91 billion in third-quarter sales. Analyst...

Novartis Slips As Generics Champ At Heart-Failure Drug In Mixed Third Quarter
Benzinga 2d
Novartis Maintains Outlook Even As Generics Bite Into Profits

Swiss pharmaceutical major Novartis AG (NYSE:NVS) reported third-quarter 2025 results on Tuesday, reaffirming its full-year guidance as strong sales from key gr...

Novartis Maintains Outlook Even As Generics Bite Into Profits
TipRanks 2d
Novartis Reports Strong Q3 2025 Results with Key Approvals

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

TipRanks 2d
Novartis announces expiration of Tourmaline Bio tender offer

Novartis (NVS) announced that its previously announced tender offer by Torino Merger Sub (TRML), a Delaware corporation and an indirect wholly owned subsidiary...

CNBC 2d
Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never be done'

Key Points The Swiss drugmaker announced its biggest deal in a decade on Sunday, as its set to buy Avidity Biosciences for about $12 billion. "We have adequate...

Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never be done'
The Wall Street Journal 2d
Novartis Posts Higher Net Profit as Key Drugs Lift Sales

Novartis confirmed its full-year guidance. fabrice coffrini/Agence France-Presse/Getty Images Novartis NOVN -0.88 %decrease; red down pointing triangle posted...

Novartis Posts Higher Net Profit as Key Drugs Lift Sales
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.